Skip to main content

Creative Medical Technology Holdings Receives Notice of Allowance for the Prevention and/or Treatment of Type 1 Diabetes Using Modulated Immune Cells

Written by Customer Service on . Posted in Public Companies.

PHOENIX, July 17, 2025 (GLOBE NEWSWIRE) — Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company specializing in regenerative medicine, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a U.S. patent application titled, “Prevention and/or Treatment of Type 1 Diabetes by Augmentation of Myeloid Suppressor Cell Activity.”  

Once granted, the patent will be in effect until at least 2040.

The patent allows a broad cell-based immunotherapy approach to treating Type 1 diabetes using the ImmCelzTM product, which includes the supercharged T regulatory cells using the Company’s proprietary cell-free solutions. This program has been validated using cells from patients with Type 1 Diabetes.

Type 1 Diabetes is an autoimmune disease in which the body’s immune system attacks and destroys insulin-producing beta cells in the pancreas.  Because beta cells produce insulin, which is essential for moving glucose (sugar) from the blood into cells for energy, the destruction of these cells leads to a deficiency in insulin and the development of diabetes.

“We believe that the use of ImmCelz to prevent and/or treat Type 1 Diabetes is regenerative immunotherapy in its truest form,” said Timothy Warbington, CEO of Creative Medical. “The treatment of Type 1 Diabetes remains a primary focus for our Company, as evidenced by our ongoing CREATE-1 clinical trial. This issuance protects the integrity of our IP portfolio and reflects the potential of our cell-based therapeutic platform to address multiple unmet medical needs.”  

About ImmCelzTM
Creative Medical’s ImmCelz platform utilizes a patient’s own extracted immune cells that are then “reprogrammed/supercharged” by culturing them outside the patient’s body with optimized cell-free factors.  The immune cells are then re-injected into the patient from whom they were extracted. The Company believes that this process endows the immune cells with regenerative properties (or “supercharges” them) on top of their original innate functions providing them with the ability to treat multiple indications.

About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is a clinical-stage biotechnology company pioneering regenerative medicine solutions for multiple indications, including pain management, neurology, and urology. The company leverages cutting-edge cell therapy technologies to develop transformative treatments aimed at improving patient outcomes.

For more information, visit www.creativemedicaltechnology.com.

Forward Looking Statements
This news release may contain forward-looking statements including, but not limited to, comments regarding the potential for the Company’s cell-based therapies and the strength of its intellectual property portfolio. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission’s website at www.sec.gov.

Contact:
Creative Medical Technology Holdings, Inc.
IR@CreativeMedicalTechnology.com

Investor Relations:
Devin Sullivan, Managing Director
The Equity Group Inc.
dsullivan@equityny.com

Conor Rodriguez
Associate
crodriguez@equityny.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.